Elixir Energy on the verge of meeting major milestones

|

Published 05-NOV-2020 09:59 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Elixir Energy Limited (ASX:EXR) has provided a promising update on operations at its Nomgon IX CBM PSC in the South Gobi region of Mongolia, just north of the Chinese border.

Aside from positive operational developments, the December quarter has been marked by strong news flow, particularly in relation to a recent statement from China which would be an important market for the group.

With China being a leader in energy usage, President Xi Jinping’s statement in October in which he committed to net zero emissions by 2060 while unexpected was embraced by those striving for a transition to carbon-neutral energy solutions.

China currently generates more than half of its electricity from coal, but natural gas is increasingly being used in the country for heating and transport.

While a transition from less coal usage to natural gas is not a silver bullet, it would at least be a stepping stone to a carbon-neutral solution.

An uptick in demand for natural gas in China would be extremely positive for Elixir Energy.

Updated contingent resource and resource booking key catalysts

Harking back to the group’s recent progress, the Nomgon 5S re-drill appraisal strat-hole well reached a total depth of 450 metres this week and has since been logged and remediated.

A total of 47 metres of net coal was intersected.

The Hutul 1S exploration well is currently drilling ahead and management anticipates it should reach total depth and be logged within the next week.

Elixir plans to drill two more exploration strat-holes in 2020 and is working with its drilling contractor on finalising local permits.

The timing of the spud of the next well is not locked in, but Elixir is aiming for this to occur within the next week.

Elixir’s shares have performed strongly in the last six months, up approximately six-fold, but the recent retracement to around 12 cents per share could represent a buying opportunity bearing in mind the exceptional surge in the September quarter when it hit a high of 18 cents.

Elixir’s managing director Neil Young pointed to factors that could see it revisit these levels in saying, “The strong net coal outcome from the Nomgon 5S Redrill well means we have now drilled five successful wells in the Nomgon sub-basin in a row.

‘’This well was a 7.3 kilometre step-out from the original Nomgon 1 discovery.

‘’Data from all the Nomgon wells will now be progressively analysed and integrated, leading firstly to updated prospective resource numbers followed by our maiden contingent resource booking.’’

The release of updated resource numbers could well have a positive impact on the group’s share price, while the release of a maiden contingent resource booking would be a major milestone for Elixir.

This will provide the numbers required to attribute a formal valuation, one which could see Elixir being the subject of a rerating should metrics demonstrate that the company is trading at a discount to its peers.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X